BR112021025531A2 - Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 - Google Patents
Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2Info
- Publication number
- BR112021025531A2 BR112021025531A2 BR112021025531A BR112021025531A BR112021025531A2 BR 112021025531 A2 BR112021025531 A2 BR 112021025531A2 BR 112021025531 A BR112021025531 A BR 112021025531A BR 112021025531 A BR112021025531 A BR 112021025531A BR 112021025531 A2 BR112021025531 A2 BR 112021025531A2
- Authority
- BR
- Brazil
- Prior art keywords
- dcn1
- nedylation
- cullin
- mediated
- pyridone
- Prior art date
Links
- 101150079125 DCN1 gene Proteins 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 4
- 102000052581 Cullin Human genes 0.000 title abstract 3
- 108700020475 Cullin Proteins 0.000 title abstract 3
- YORKCBORGGOPFM-UHFFFAOYSA-N 1h-pyrazole;1h-pyridin-2-one Chemical compound C=1C=NNC=1.O=C1C=CC=CN1 YORKCBORGGOPFM-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150016407 UBE2M gene Proteins 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2. um modulador de nedilação de cullin mediado por dcn1/2; um método para tratar distúrbios associados a disfunção de dcn1 e/ou ubc12, doença de alzheimer, outras doenças neurodegenerativas, infecções bacterianas ou infecções virais; e um método para tratar câncer são fornecidos. o modulador de nedilação de cullin mediado por dcn1/2 inclui um composto definido de acordo com a fórmula i divulgada neste documento. os métodos incluem administrar a um mamífero uma quantidade terapeuticamente eficaz de um composto definido de acordo com a fórmula i. também é fornecida neste documento uma composição farmacêutica incluindo uma quantidade terapeuticamente eficaz de um composto definido de acordo com a fórmula i, ou um sal farmaceuticamente aceitável do mesmo, e um veículo farmaceuticamente aceitável.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864331P | 2019-06-20 | 2019-06-20 | |
| PCT/US2020/038998 WO2020257790A1 (en) | 2019-06-20 | 2020-06-22 | Pharmaceutically active pyrazolo-pyridone modulators of dcn1/2-mediated cullin neddylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025531A2 true BR112021025531A2 (pt) | 2022-03-03 |
Family
ID=74037593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025531A BR112021025531A2 (pt) | 2019-06-20 | 2020-06-22 | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220280488A1 (pt) |
| EP (1) | EP3986893A4 (pt) |
| JP (1) | JP2022537403A (pt) |
| KR (1) | KR20220044479A (pt) |
| CN (1) | CN114599650A (pt) |
| AU (1) | AU2020298330A1 (pt) |
| BR (1) | BR112021025531A2 (pt) |
| CA (1) | CA3144075A1 (pt) |
| MX (1) | MX2021016133A (pt) |
| WO (1) | WO2020257790A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3225285A1 (en) * | 2021-07-13 | 2023-01-19 | Alessandro Boezio | Pi3k.alpha. inhibitors and methods of use thereof |
| CN114805347B (zh) * | 2022-05-12 | 2023-10-20 | 贵州大学 | 一种有机催化合成手性吡唑并[3,4-b]吡啶酮类化合物及应用 |
| WO2023244691A1 (en) * | 2022-06-14 | 2023-12-21 | University Of Kentucky Research Foundation | Compositions, and methods for inhibiting dcn1-ubc12 interaction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2809892C (en) * | 2010-09-02 | 2019-05-28 | Merck Patent Gmbh | Pyrazolopyridinone derivatives as lpa receptor antagonists |
| EP3349743B1 (en) * | 2015-09-18 | 2022-04-06 | St. Jude Children's Research Hospital | Methods and compositions of inhibiting dcn1-ubc12 interaction |
| CN107271687A (zh) * | 2017-07-14 | 2017-10-20 | 郑州大学 | 利用HTRF技术筛选UBC12/Dcn1小分子抑制剂的方法 |
-
2020
- 2020-06-22 MX MX2021016133A patent/MX2021016133A/es unknown
- 2020-06-22 US US17/618,952 patent/US20220280488A1/en active Pending
- 2020-06-22 KR KR1020227000394A patent/KR20220044479A/ko unknown
- 2020-06-22 CA CA3144075A patent/CA3144075A1/en active Pending
- 2020-06-22 AU AU2020298330A patent/AU2020298330A1/en active Pending
- 2020-06-22 BR BR112021025531A patent/BR112021025531A2/pt unknown
- 2020-06-22 CN CN202080057940.8A patent/CN114599650A/zh active Pending
- 2020-06-22 JP JP2021575979A patent/JP2022537403A/ja active Pending
- 2020-06-22 WO PCT/US2020/038998 patent/WO2020257790A1/en active Application Filing
- 2020-06-22 EP EP20826136.2A patent/EP3986893A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114599650A (zh) | 2022-06-07 |
| KR20220044479A (ko) | 2022-04-08 |
| AU2020298330A1 (en) | 2022-01-27 |
| CA3144075A1 (en) | 2020-12-24 |
| EP3986893A4 (en) | 2023-07-12 |
| MX2021016133A (es) | 2022-07-19 |
| EP3986893A1 (en) | 2022-04-27 |
| US20220280488A1 (en) | 2022-09-08 |
| WO2020257790A1 (en) | 2020-12-24 |
| JP2022537403A (ja) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR0211742A (pt) | Derivados de aminoisoxazole ativos como inibidores de cinase | |
| BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
| BR0211807A (pt) | Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
| BRPI0514735A (pt) | derivados de piridino sulfonamida como moduladores do receptor de quimiocina | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| PH12019500597A1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| BR112021025558A2 (pt) | Formulação estável de cetrorelix e processo para a preparação de uma formulação estável | |
| BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
| BR112023017999A2 (pt) | Obicetrapibe para tratamento de demências | |
| BR112022017779A2 (pt) | Imunomodulação de azaletos de o-het-arila | |
| EP4035669A4 (en) | MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |